Skip to content
★ Sign in to follow
何

何仕

Executive
方盛制药
Total declarations
8
Company
1
▲ Purchases (8 ops.)
€91k
▼ Sales (0 ops.)
—

Latest filing published 03 Jun 2024 for 方盛制药, €27k.

Filing timeline

BuySale
何仕

Insider track record

Disclosed buys
8
Disclosed sells
0
Signal history

Closed purchases

Market purchases
8
Positive at T+90
50%
Median T+90
+0.5%

Based on 8 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

  • Filed 03 Jun 2024 · 888 days ago · €27k
    -7.2%
    Entry CN¥11.63 · Close at T+365 CN¥10.79
  • Filed 30 May 2024 · 892 days ago · €4,576
    -9.0%
    Entry CN¥11.84 · Close at T+365 CN¥10.78
  • Filed 26 Apr 2024 · 926 days ago · €29k
    -14.5%
    Entry CN¥11.58 · Close at T+365 CN¥9.90
  • Filed 25 Apr 2024 · 927 days ago · €1,515
    -13.8%
    Entry CN¥11.49 · Close at T+365 CN¥9.90
  • Filed 24 Apr 2024 · 928 days ago · €1,507
    -13.3%
    Entry CN¥11.52 · Close at T+365 CN¥9.99

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

何仕: trading record in brief

何仕 is a declared insider of 方盛制药 (chief executive), with filings sourced from SSE / SZSE (CSRC). The record holds 8 filings, for trades running from 22 December 2023 to 3 June 2024.

The open-market record is one-sided, with 8 purchases worth €91k and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. In 2024 alone, the filings show 5 purchases and no sales.

In size, the median ticket on the buying side is €8,894. No cluster: in 8 purchases, no other insider of the company bought within 30 days. After 8 purchases with a full 90-day history, the hit rate stands at 50% and the median 90-day move at +0.5%. Past outcomes like these are no guarantee of what comes next.

The latest filing, published on 3 June 2024, reports an open-market purchase of €27k in 方盛制药. Half of the filings or more reach the SSE / SZSE (CSRC) feed on the day of the trade. Until a filing is published, the market cannot know about the trade. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.

Companies and markets linked to 何仕

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations8 total
  • ▲
    高级管理人员Executives方盛制药
    205,355 CNY14SSE
    17,400 shares29.0% of flowA股XSHGSSE:173000007715424800
    Canonical exit: 1 Sept 2024 (T+90)
  • ▲
    高级管理人员Executives方盛制药
    35,211 CNY12SSE
    3,000 shares5.0% of flowA股XSHGSSE:173000007702092800
    Canonical exit: 28 Aug 2024 (T+90)
  • ▲
    高级管理人员Executives方盛制药
    218,120 CNY14SSE
    19,000 shares31.4% of flowA股XSHGSSE:173000007553186780
    Canonical exit: 25 Jul 2024 (T+90)
  • ▲
    高级管理人员Executives方盛制药
    11,540 CNY11SSE
    1,000 shares1.7% of flowA股XSHGSSE:173000007543172000
    Canonical exit: 24 Jul 2024 (T+90)
  • ▲
    高级管理人员Executives方盛制药
    11,480 CNY11SSE
    1,000 shares1.6% of flowA股XSHGSSE:173000007534840540
    Canonical exit: 23 Jul 2024 (T+90)
  • ▲
    高级管理人员Executives方盛制药
    103,340 CNY12SSE
    10,000 shares14.5% of flowA股XSHGSSE:173000007190078370
    Canonical exit: 26 Mar 2024 (T+90)
  • ▲
    高级管理人员Executives方盛制药
    10,620 CNY11SSE
    1,000 shares1.5% of flowA股XSHGSSE:173000007190078340
    Canonical exit: 25 Mar 2024 (T+90)
  • ▲
    高级管理人员Executives方盛制药
    109,600 CNY13SSE
    10,000 shares15.4% of flowA股XSHGSSE:173000007180669820
    Canonical exit: 21 Mar 2024 (T+90)

8 of 8 declarations